NEW YORK (360Dx) – Laboratory Corporation of America today reported 8 percent year-over-year revenue growth companywide for the third quarter while the company's diagnostics revenues were flat.

Total revenues for the quarter was $2.83 billion, up from $2.62 billion in the third quarter of 2017, and missed the consensus Wall Street estimate of $2.84 billion.

Growth was driven largely by acquisitions, which accounted for 6.5 percent of growth, and strong performance in the company's Covance drug development business. Organically, revenues were up almost 3 percent.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease. 


In this webinar, Dr. Wendy Béguelin of Weill Cornell Medicine will discuss how she used the BD Rhapsody single-cell RNA-seq platform and YFP floxed reporter mouse models to study how lymphoma-associated mutations disrupt the immune system by affecting GC B-cell states, explaining the biology of initiation of low-grade follicular lymphoma.

Sponsored by

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.